Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

Autor: Cre´moux, P. De, Die´ras, V., Doussal, V. Le, Vincent-Salomon, A., Tubiana-Hulin, M., Pierga, J.-Y., Spyratos, F., Magdele´nat, H., Pouillart, P.
Zdroj: European Journal of Cancer; 1999, Vol. 35 Issue: 1 pS86-S86, 1p
Databáze: Supplemental Index
Externí odkaz: